期刊文献+

肝脏恶性肿瘤的局部微创介入治疗进展 被引量:1

Advances in Minimally Invasive Local Interventions for Hepatocellular Carcinoma
下载PDF
导出
摘要 对局部微创治疗肝癌的手段,包括经动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)、选择性内放射治疗(selective internal radiation therapy,SIRT)、射频(radiofrequency ablation,RFA)/微波消融(microwave ablation,MWA)、冷冻治疗(cryoablation)、激光诱导肿瘤治疗(laser-induced thermal therapy,LITT)、不可逆电穿孔(irreversible electroporation,IRE)、高功率超声聚焦消融(high-intensity focused ultrasound,HIFU)、无水乙醇注射治疗(percutaneous ethanol injection,PEI)和中医外治等方法的优缺点、适用人群、疗效等进行小结,为临床应用这些技术治疗肝癌提供参考。 The article summarizes the advantages and disadvantages,the applicable population,clinical effects of the measures of local minimally invasive therapies for hepatocellular carcinoma,including TACE,SIRT and RFA/MWA,cryoablation,LITT,IRE,HIFU,PEI as well as TCM external therapy,in order to provide the reference for clinical application of these technologies for the disease.
作者 刘光德 张灿明 王斌哲 LIU Guangde;ZHANG Canming;WANG Binzhe(The First Expatriate Clinic of Hospital 940 of PLA Joint Logistics Support Force,Lanzhou 730050,China)
出处 《西部中医药》 2023年第10期172-177,共6页 Western Journal of Traditional Chinese Medicine
关键词 肝癌 经皮肝动脉化疗栓塞 选择性内照射 消融 中医外治 hepatocellular carcinoma transcatheter arterial chemoembolization selective internal radiation therapy ablation TCM external therapy
  • 相关文献

参考文献3

二级参考文献118

  • 1Nakashima T.Pathology of hepatocellular carcinomartumor thrombus of the portal vein[J].Acta Hepathol Jap,1984,25:120.
  • 2Yamanaka W,Okamoto E,Fujihara S,et al.Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection[J]? Cancer,1992,70:2263 -2267.
  • 3Katsumori T,Fujita M,Takahashi T,et al.Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein[J].Cardiovasc Intervent Radiol,1995,18:217-221.
  • 4Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0].
  • 5Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI:10.3322/canjclin.55.2.74].
  • 6Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer:worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16 [PMID: 15508102 DOI: 10.1053/j.gastro.2004.09.011].
  • 7European Association For The Study Of The Liver; EuropeanOrganisation For Research And Treatment Of Cancer. EASLEORTCclinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001].
  • 8Lencioni R. Chemoembolization in patients with hepatocellularcarcinoma. Liver Cancer 2012; 1: 41-50 [PMID: 24159570 DOI:10.1159/000339019].
  • 9Llovet JM, Bruix J. Systematic review of randomized trialsfor unresectable hepatocellular carcinoma: Chemoembolizationimproves survival. Hepatology 2003; 37: 429-442 [PMID:12540794].
  • 10Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU,Ahn SH, Chon CY, Han KH. Radiological response predictssurvival following transarterial chemoembolisation in patients withunresectable hepatocellular carcinoma. Aliment Pharmacol Ther2012; 35: 1343-1350 [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x].

共引文献23

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部